Press releases
21/04/2022 Mabion reviews breakthrough year 2021 and announces increased growth in 2022
28/01/2022 Mabion joins the Great Orchestra of Christmas Charity (WOŚP) and donates headquarters visit for auction at 30th Grand Finale
18/01/2022 Mabion and Novavax expand scope of collaboration to include additional key elements of the COVID-19 vaccine manufacturing process
23/12/2021 Mabion executes agreement with Novavax and produces first full batch of antigen for COVID-19 vaccine
20/12/2021 Novavax COVID-19 vaccine receives positive recommendation from European Medicines Agency and approval for use in European Union countries. Mabion executes Novavax contract as planned and in full agreement with partner.
8/10/2021 Mabion Announces Commercial Manufacturing Agreement for Novavax COVID-19 Vaccine
03/03/2021 Mabion and the Polish Development Fund signed a preliminary agreement on capital support for the production of a vaccine for COVID-19
03/03/2021 Mabion Announces signing an Agreement with Novavax for Large-Scale Vaccine Manufacturing Feasibility Assessment
22/02/2021 Mabion implements next stage of its financial strategy – the Company convenes EGSM to conduct a public share offering and raise up to PLN 200 million to complete the development and market launch of MabionCD20
28/01/2021 Mabion S.A. updates its financial strategy, seeks a strategic investor and convenes a GSM to pass a resolution on issue of shares
29/10/2020 Mabion and Vaxine enter into Memorandum of Understanding to Develop, Manufacture and Commercialize a COVID-19 Vaccine in the EU
30/07/2020 Mabion initiates the national and regional PCT phases of the patent application for the use of MabionCD20 in the treatment of Multiple Sclerosis (MS)
15/07/2020 Company receives a loan from a shareholder for the repayment of loan from Santander bank
19/05/2020 The Management Board and the Supervisory Board of Mabion S.A. in favour of share issue to support the next phase of work on the registration of MabionCD20 in several regulated markets
12/11/2019 Mabion had submitted answers to the second round of questions by the European Medicines Agency (EMA) received as part of the Day 180 stage of the registration procedure for MabionCD20​
10/2018 Mabion submits a second registration application to EMA for the MabionCD20 d
06/2018 Mabion S.A. completes marketing authorisation application for flagship drug, MabionCD20, to the European Medicines Agency (EMA)
03/2018 Mabion Announces a USD$51.0 Million Private Placement with European and US Investors
04/09/2017 Mabion S.A. with a new innovative indication in the treatment of multiple sclerosis for MabionCD20
31/03/2017 Mabion S.A. adopts a strategy plan concerning development of medicinal products
14/12/2016 Mabion S.A. faces international challenges and welcomes new President of the Board
10/11/2016 Mabion S.A. signs supply and commercialization agreement with Mylan regarding MabionCD20 for EU markets
22/06/2016 Mabion S.A. is on track for completing the MabionCD20 clinical programme and signing a partnering contract
22/03/2016 Biosimilar rituximab – many have started – only a few will succeed